Biology Atlas

Map / Modalities

modality · intermediate · complete

Antisense oligonucleotide (ASO)

An antisense oligonucleotide (ASO) is a short, chemically armoured single strand of nucleic acid that pairs with one RNA to destroy it, block it or change how it is spliced.

Also called: ASO, antisense oligo, gapmer, splice-switching oligonucleotide

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

In brief

An antisense oligonucleotide is a short, chemically armoured strand that pairs with one RNA. Depending on its design it either recruits an enzyme that cuts the RNA, so less protein is made, or it just sits on the RNA and changes how it is spliced, so a different protein is made. It is chosen by sequence, injected, and lasts for months. 12

Established

His guess: it acts at the RNA level

His words: "Antisense oligos, which I guess intervene at the RNA level." 3

Amit's hypothesis

Checking the guess against the evidence

Correct, and the sources add a refinement. An antisense oligonucleotide acts on RNA by base-pairing with it, as the FDA label for nusinersen and the oligonucleotide chemistry review describe. But "at the RNA level" covers two quite different actions: destroying the RNA (a gapmer, via the enzyme RNase H) or only blocking a site so splicing changes (a steric blocker such as nusinersen). The same sequence logic can lower a protein or switch on a different version of it. 12

Established

Two modes: cut or block more

The deciding structural fact is whether the oligo and its target RNA look like a DNA:RNA hybrid. RNase H cleaves the RNA strand of such a hybrid; the review says RNA:RNA duplexes do not elicit it, which is why a gapmer design is needed to recruit it.

A gapmer has a central stretch of DNA-like letters (the gap) flanked by modified wings. The wings give stability and binding; the gap gives the enzyme a substrate. The 5-10-5 layout (a 20-mer) is used by mipomersen, inotersen and volanesorsen. Result: the target RNA is destroyed and the protein falls.

A steric blocker has every position modified, so the enzyme cannot engage. Nusinersen is an 18-mer of this kind. It occupies a site and changes what the splicing machinery does. Which enzyme isoform does the cutting is not named in the sources opened. 1

Reported, not yet replicated

The chemistry is the drug more

Natural nucleic acid does not survive. Two standard fixes appear on the nusinersen label: phosphorothioate links (one oxygen replaced by sulfur) and a 2'-O-methoxyethyl sugar. The review reports that phosphorothioate DNA binds plasma proteins, mainly albumin and alpha2-macroglobulin, and that oligo chemistry in general affects Toll-like-receptor binding, coagulation and complement activation (it does not tie each toxicity to one chemistry). MOE adds nuclease resistance and about 1 degree C of melting-temperature gain per residue. 12

Reported, not yet replicated

Delivery decides the design more

After intravenous dosing an all-phosphorothioate MOE gapmer had a plasma half-life of 15 to 45 minutes in five species including human. Two routes dominate.

To the brain and cord: injection into the spinal fluid, because the drug does not cross the blood-brain barrier well. In the nusinersen label the plasma trough is low compared with CSF.

To the liver: a sugar tag (triantennary GalNAc) binds a receptor on liver cells only. In mice it gave 6 to 10 fold higher potency for a MOE gapmer and about 60 fold for shorter cEt gapmers. Mouse potency is not human potency; only the abstract was read. 124

Reported, not yet replicated

How long it lasts and how it is stopped more

Nusinersen: terminal half-life 135 to 177 days in CSF and 63 to 87 days in plasma, cleared by exonucleases. The 2016 label doses months apart. The only way to stop is to stop dosing and wait for washout; this is reasoned from the half-lives. Later label revisions were not opened. This describes a label, not guidance for any person. 2

Reported, not yet replicated

One class, two fates: nusinersen and tominersen more

Nusinersen switches a splice in spinal muscular atrophy: in the randomised sham-controlled ENDEAR trial the final motor-milestone response was 37 of 73 (51 percent) versus 0 of 37, with a hazard ratio of 0.53 for death or permanent ventilation.

Tominersen aimed to lower huntingtin: CSF mutant huntingtin fell by 47 percent on the every-2-months dose, yet that arm did worse than placebo and dosing was stopped in March 2021. The cause is a hypothesis, not a finding. See the two drug records. 5678

Reported, not yet replicated

Splice switching in detail (SMA) deep

The SMN1 gene is lost or defective in spinal muscular atrophy; the near-identical SMN2 gene mostly skips exon 7. The trial protocol puts the skipping at up to about 90 percent and describes an intronic silencer (ISS-N1). A tiling screen of 31 ASOs found two that strongly raised SMN2 exon 7 inclusion in transgenic mouse liver and kidney (abstract only). The nusinersen label says it binds a sequence in the intron downstream of exon 7. The gene is turned up, not knocked down: the opposite of a gapmer. See concepts/splicing. 9102

Reported, not yet replicated

Backbone class toxicities deep

On the nusinersen label, platelets fell below the lower limit of normal in 6 of 56 treated patients (11 percent) versus 0 of 28 sham, none under 50,000, and urine protein was raised in 17 of 51 (33 percent) versus 5 of 25 (20 percent); the label asks for monitoring of both. The review links oligo chemistry to Toll-like-receptor binding, coagulation and complement activation but does not tie each effect to phosphorothioate alone. 21

Reported, not yet replicated

Where it breaks deep

A gapmer cuts any RNA with enough match, so sequence screening and checks on related transcripts are needed; splice switchers can shift unintended exons. Exposure is not effect: a big fall in the target did not guarantee benefit (tominersen). Delivery is compartment-limited. Animal potency gains are not human potency. For tominersen the more frequently dosed arm showed more of the neuron-injury marker NfL than placebo (+10 percent against +6 percent) while the protein marker fell, which separates "lower the protein" from "tolerate the drug" in the data. The evidence read here is mostly abstracts plus the 2016 label, the protocol and a sponsor-written summary. 162

Reported, not yet replicated

What it is

A short strand of nucleic acid, around 18 to 20 letters for the approved examples, built to pair with one RNA by Watson-Crick base-pairing. Natural DNA or RNA would be chewed up by nucleases, so the real drug is the sequence plus a chemical armour: the phosphate links are swapped for phosphorothioate and the sugar carries a 2'-O-methoxyethyl (MOE) group, as on the nusinersen label. 12

Established

Intervenes at

Same as small molecule

The path from disease to drug still runs through a causal target, a potency measure, safety testing and a trial against a control. The target is chosen by what the RNA looks like in sequence, not by a three-dimensional pocket, but the failure points are familiar: engagement of the target is not the same as benefit, and class toxicities appear in the clinic. 126

Our inference

Changes downstream

Potency becomes how much RNA is destroyed or how much the splicing shifts per tissue exposure, not binding in a pocket. Selectivity becomes sequence uniqueness: a cutting design (gapmer) can cut any RNA with enough match, so many sequences are screened along the target (tiling). Toxicity is partly a property of the backbone (platelet and kidney effects on the nusinersen label). Dose spacing follows how long the drug stays in the target tissue; the label dose interval of months follows from a cerebrospinal fluid half-life of 135 to 177 days. Manufacturing is chemical synthesis of a polymer rather than a small-molecule route; that part was not researched here. 1210

Our inference

Delivery

Naked ASOs are large, charged and cleared quickly from blood: an all-phosphorothioate MOE gapmer had a plasma half-life of 15 to 45 minutes across mouse, rat, dog, monkey and human. They do not cross the blood-brain barrier well, so for brain and cord disease nusinersen is injected by lumbar puncture into the cerebrospinal fluid. For the liver, a triantennary GalNAc sugar tag binds a receptor found on liver cells; in mice it improved the potency of a MOE gapmer 6 to 10 fold, about 60 fold with shorter cEt gapmers, and the tag is clipped off inside the cell. Subcutaneous absorption of that gapmer was 80 to 100 percent. 124

Reported, not yet replicated

Persistence

Months, set by the chemistry and the tissue. Nusinersen has a mean terminal half-life of 135 to 177 days in CSF and 63 to 87 days in plasma and is cleared by exonucleases, not CYP450 enzymes; the 2016 label spaces doses months apart. There is no off switch: the drug is not a gene, so effect fades by clearance after dosing stops. That last point is reasoning from the half-lives, not a sourced statement. 21

Our inference

Examples

Teach this

In one sentence

An antisense oligonucleotide is a chemically armoured strand that pairs with one RNA and either gets it cut or changes how it is spliced. 12

Established

The five-minute version

Small molecules usually grab a protein. An antisense oligonucleotide acts one step earlier, on the RNA, chosen by sequence rather than a pocket. Natural strands do not survive, so the backbone is armoured (phosphorothioate links, MOE sugars). If the design leaves a DNA centre the enzyme RNase H cuts the RNA and the protein falls; if every position is modified the oligo only blocks a site, as nusinersen does to switch on a different splice of SMN2. It cannot cross the blood-brain barrier, so for brain and cord it is injected into spinal fluid, where it lasts months (half-life 135 to 177 days for nusinersen). Nusinersen worked in a sham-controlled trial; tominersen lowered its target and still did not help. The lesson is that hitting the RNA is the easy half. 1256

Reported, not yet replicated

What a listener will ask

Is it gene therapy?

No. It does not change DNA and it is not a gene; it fades by clearance, so dosing has to continue (reasoned from the half-lives in the label). 12

Reported, not yet replicated

Does it always destroy the RNA?

No. A gapmer recruits RNase H to cut; a steric blocker like nusinersen only blocks a site and changes splicing. 12

Reported, not yet replicated

Why is the brain delivery route an injection?

The drug is large and charged and does not cross the blood-brain barrier well, so it is injected into the spinal fluid. 12

Reported, not yet replicated

The common wrong idea

Antisense drugs work by destroying a bad RNA.

That is only one mode (the gapmer); nusinersen leaves the RNA intact and changes how it is spliced so more of a good protein is made.

The one citation to hand over: 1

Still open here

Linked from

Sources

  1. Egli, M., Manoharan, M.. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research (2023). review; opened 2026-11-17 all records citing this
  2. U.S. Food and Drug Administration (label text supplied by the sponsor). SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information (initial US approval 2016, revised 12/2016). FDA Drugs@FDA label archive (2016). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
  4. Prakash, T. P., et al.. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Research (2014). paper; opened 2026-11-17 all records citing this
  5. Finkel, R. S., et al.. Nusinersen versus sham control in infantile-onset spinal muscular atrophy (ENDEAR). New England Journal of Medicine (2017). paper; opened 2026-11-17 all records citing this
  6. F. Hoffmann-La Roche Ltd (sponsor). GENERATION HD1 (BN40423) final results: plain-language summary, September 2023. Roche forpatients (2023). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  7. BioSpace. Ionis and Roche halt Huntington's disease trials. BioSpace (2021). news, not peer reviewed; opened 2026-11-17 all records citing this
  8. HDBuzz. HDBuzz explainer on the GENERATION HD1 results (article 354). HDBuzz (patient-community science news) (2023). news, not peer reviewed; opened 2026-11-17 all records citing this
  9. Sponsor-written trial protocol. Clinical trial protocol NCT02594124 (nusinersen extension study), full document. ClinicalTrials.gov large documents (2015). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  10. Hua, Y., et al.. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. American Journal of Human Genetics (2008). paper; opened 2026-11-17 all records citing this
  11. Yamamoto, et al.. [Descriptive title, not as printed] Exposure-response analysis of tominersen across four studies. British Journal of Clinical Pharmacology (2025). paper; opened 2026-11-17 all records citing this
  12. Tabrizi, S. J., et al.. Targeting huntingtin expression in patients with Huntington disease. New England Journal of Medicine (2019). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (2)

This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
complete
Last updated
2026-11-17
Record
content/modalities/antisense-oligonucleotide.json